8-K current report · filed Nov 10, 2026

Humacyte, Inc. (HUMA) 8-K Current Report: November 10, 2026

Item 2.02Item EX-99.1HUMA overview

Short answer

Humacyte, Inc. (HUMA) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal Q3 2026 results for quarter ended September 30, 2026.

Humacyte, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal Q3 2026 results for quarter ended September 30, 2026
  • Humacyte press release furnished as Exhibit 99.1, containing the detailed financial results
  • Results announcement gives investors an update on operating performance and financial condition

Item EX-99.1 · Exhibit EX-99.1

  • Symvess Q3 sales $1.0M, up 151% sequentially and 45% year over year, with ordering hospitals rising 44% to 49
  • October sales reached $0.8M, while management targets at least doubling Q3 sales in Q4, supporting commercial traction but raising execution expectations
  • Product revenue $1.023M versus cost of goods sold $1.429M, indicating negative gross margin during early commercialization
  • Cash and restricted cash $64.9M, with nine-month operating cash burn $62.1M, highlighting continuing financing risk despite lower R&D spending
  • Planned November 2026 sBLA filing for dialysis access and newly initiated Phase 2a CABG study expand catalysts, but both remain regulatory or clinical-stage opportunities

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Humacyte, Inc. 8-K filings

Get the next HUMA 8-K as it lands

Follow HUMA for push alerts, or ask the research agent what this filing means.